Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
October 19 2023 - 3:00AM
Macomics Ltd, a leader in macrophage drug discovery, announces that
it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive
Director.
Based in the UK and CEO of Cambridge,
UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ: BCYC), Kevin
brings two decades of biotech and pharma experience to Macomics. In
addition to his seat on Bicycle’s board of directors, he is also a
non-executive director of Alchemab Therapeutics Ltd.
Kevin has led Bicycle Therapeutics since 2015,
steering it through its strategic growth including various
collaborations and financings including through its listing on
NASDAQ in 2019. He joined Bicycle from Pfizer, where he served as
senior vice president and CSO of the Rare Disease Research Unit. In
that role, he held responsibility for more than 20 novel programs
across the full spectrum of research and development, established
Pfizer’s rare disease strategy, conceptualized and implemented the
company’s gene therapy strategy with the creation of the Genetic
Medicine Institute and founded the Rare Disease Research
Consortium. Prior to joining Pfizer, Kevin worked at
GlaxoSmithKline (GSK) and, in addition to leading the formation of
multiple strategic commercial and academic partnerships, he led
epigenetics research and was responsible for the creation of the
EpiNova Discovery Performance Unit. Before joining GSK, he lectured
at Warwick University Medical School and founded Cambridge
Biotechnology (acquired by Biovitrum) and Neurosolutions.
Kevin studied pharmaceutical sciences at
Nottingham University, followed by a Ph.D. in pharmacology at
Cambridge University. He undertook postdoctoral training as a
Wellcome Trust International Prize Fellow before joining the Parke
Davis Research Unit in Cambridge, U.K. An author on over 100
peer-reviewed scientific publications, he has an MBA from Warwick
Business School and has been awarded an honorary Chair in Molecular
Pharmacology from the University of Warwick.
Macomics is exploiting the potential of
macrophage-targeted approaches to develop first-in-class medicines
to address disease of high unmet medical need. The company’s
ENIGMAC macrophage drug discovery platform allows access to
previously hidden disease specific macrophage targets: it
integrates large volume human data sets, next generation human
macrophage cell models, and proprietary macrophage genome editing
capability to discover novel targets, unlock new disease biology,
and de-risk clinical translation. Macrophages are key to multiple
diseases of high unmet medical need, including as key mediators of
solid tumour immunosuppression and pathological inflammation in
chronic inflammatory disorders.
Kevin Lee, Macomics Board Director,
said, “Macomics is shaping up as an exciting emerging UK
biotech with a powerful macrophage platform and drug discovery
approach that is already demonstrating its potential to identify
commercially exciting targets and validate antibody drug
candidates. The company is at an exciting stage of its development,
and I look forward to working with the Board and the Macomics team
to help it deliver on its potential.”
Stephen Myatt, CEO of Macomics,
said, “I am delighted to welcome Kevin to our Board. His
experience in building Bicycle Therapeutics and previously in his
pharma roles will be extremely valuable in helping us to exploit
our platform and advance our portfolio towards clinical
development. I look forward to work closely with Kevin to bring
next generation macrophage targeting therapeutics to cancer
patients.”
About Macomics –
www.macomics.com
Macomics Ltd is a macrophage drug discovery
company with a world-leading macrophage drug discovery platform,
developing first-in-class medicines to deliver transformational
impact for patients with macrophage-driven diseases: macrophages
are key to multiple diseases of high unmet medical need, including
as key mediators of solid tumour immunosuppression and pathological
inflammation in chronic inflammatory disorders.
The company is progressing a diversified
portfolio of therapies targeting disease specific macrophages
towards the clinic. Its ENIGMAC macrophage drug discovery platform
enables identification and validation of novel macrophage
therapeutic targets and provides a translationally relevant path to
clinic through the development of more physiologically relevant
human macrophage models combined with proprietary gene editing
technology.
The company was co-founded in 2020 by Prof.
Jeffrey Pollard and Dr. Luca Cassetta, University of Edinburgh,
internationally recognised leaders in macrophage biology. It has
R&D and office facilities in Edinburgh and Cambridge, UK. The
company’s financing was led by Epidarex Capital and the company is
backed by Scottish Enterprise, LifeLink Ventures and Caribou
Property Limited.
Follow us on LinkedIn and
https://twitter.com/MacomicsL
For further information please contact:
Macomics
At the Company - Steve Myatt, CEO, Macomics
E: myatt@macomics.com
Media enquiries (for Macomics) - Sue Charles,
Charles Consultants T: +44 (0)7968 726585
E: sue@charles-consultants.com
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Sep 2023 to Sep 2024